Tarbox Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-38
| Closed | -$27K | – | 779 |
|
|
2022
Q1 | $27K | Sell |
38
-16
| -30% | -$10.1K | 0.01% | 248 |
|
|
2021
Q4 | $34K | Buy |
54
+1
| +2% | +$615 | 0.01% | 279 |
|
|
2021
Q3 | $32K | Hold |
53
| – | – | 0.01% | 305 |
|
|
2021
Q2 | $30K | Hold |
53
| – | – | 0.01% | 315 |
|
|
2021
Q1 | $25K | Hold |
53
| – | – | ﹤0.01% | 286 |
|
|
2020
Q4 | $26K | Sell |
53
-3
| -5% | -$1.62K | 0.01% | 265 |
|
|
2020
Q3 | $31K | Buy |
56
+3
| +6% | +$1.82K | 0.01% | 234 |
|
|
2020
Q2 | $33K | Buy |
53
+4
| +8% | +$2.27K | 0.01% | 218 |
|
|
2020
Q1 | $24K | Buy |
49
+26
| +113% | +$10.7K | 0.01% | 230 |
|
|
2019
Q4 | $9K | Buy |
23
+2
| +10% | +$673 | ﹤0.01% | 402 |
|
|
2019
Q3 | $6K | Buy |
21
+7
| +50% | +$2.07K | ﹤0.01% | 433 |
|
|
2019
Q2 | $4K | Sell |
14
-7
| -33% | -$2.33K | ﹤0.01% | 523 |
|
|
2019
Q1 | $9K | Hold |
21
| – | – | ﹤0.01% | 326 |
|
|
2018
Q4 | $8K | Buy |
21
+7
| +50% | +$2.56K | ﹤0.01% | 324 |
|
|
2018
Q3 | $6K | Hold |
14
| – | – | ﹤0.01% | 385 |
|
|
2018
Q2 | $5K | Sell |
14
-9
| -39% | -$2.81K | ﹤0.01% | 396 |
|
|
2018
Q1 | $8K | Buy |
23
+1
| +5% | +$348 | ﹤0.01% | 345 |
|
|
2017
Q4 | $8K | Buy |
22
+1
| +5% | +$405 | ﹤0.01% | 339 |
|
|
2017
Q3 | $9K | Buy |
21
+3
| +17% | +$1.43K | ﹤0.01% | 320 |
|
|
2017
Q2 | $9K | Hold |
18
| – | – | ﹤0.01% | 310 |
|
|
2017
Q1 | $7K | Hold |
18
| – | – | ﹤0.01% | 329 |
|
|
2016
Q4 | $7K | Hold |
18
| – | – | ﹤0.01% | 296 |
|
|
2016
Q3 | $7K | Hold |
18
| – | – | ﹤0.01% | 287 |
|
|
2016
Q2 | $6K | Sell |
18
-6
| -25% | -$2.31K | ﹤0.01% | 304 |
|
|
2016
Q1 | $9K | Buy |
24
+5
| +26% | +$2.06K | 0.01% | 262 |
|
|
2015
Q4 | $10K | Hold |
19
| – | – | 0.01% | 232 |
|
|
2015
Q3 | $9K | Sell |
19
-2
| -10% | -$1.07K | 0.01% | 251 |
|
|
2015
Q2 | $11K | Buy |
21
+3
| +17% | +$1.46K | 0.01% | 222 |
|
|
2015
Q1 | $8K | Hold |
18
| – | – | 0.01% | 276 |
|
|
2014
Q4 | $7K | Hold |
18
| – | – | 0.01% | 291 |
|
|
2014
Q3 | $6K | Buy |
18
+3
| +20% | +$1K | 0.01% | 301 |
|
|
2014
Q2 | $4K | Hold |
15
| – | – | ﹤0.01% | 329 |
|
|
2014
Q1 | $4K | Hold |
15
| – | – | ﹤0.01% | 348 |
|
|
2013
Q4 | $4K | Buy |
+15
| New | +$4.31K | ﹤0.01% | 395 |
|
Other funds holding REGN
Tarbox Family Office's REGN Position: Q2 2022 in Review
Tarbox Family Office sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 38 shares — an estimated $27K sold.
Tarbox Family Office first reported a position in REGN in Q4 2013 and held it in 34 quarters. The position peaked at $34K in Q4 2021. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.
- Tarbox Family Office reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
- Tarbox Family Office sold 38 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $27K.
- Tarbox Family Office first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 34 quarters.
- Tarbox Family Office's Regeneron Pharmaceuticals position peaked at $34K in Q4 2021.
- 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.
Based on Tarbox Family Office's 13F filing for Q2 2022, filed 19 Jul 2022.